0000899243-21-036636.txt : 20210920 0000899243-21-036636.hdr.sgml : 20210920 20210920183315 ACCESSION NUMBER: 0000899243-21-036636 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210217 FILED AS OF DATE: 20210920 DATE AS OF CHANGE: 20210920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: VAN BEEK JEROEN B CENTRAL INDEX KEY: 0001743662 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39409 FILM NUMBER: 211264369 MAIL ADDRESS: STREET 1: C/O TRICIDA, INC. STREET 2: 7000 SHORELINE COURT, SUITE 201 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allovir, Inc. CENTRAL INDEX KEY: 0001754068 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 831971007 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 433-2605 MAIL ADDRESS: STREET 1: 139 MAIN STREET, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: ViraCyte, Inc. DATE OF NAME CHANGE: 20180924 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-17 0 0001754068 Allovir, Inc. ALVR 0001743662 VAN BEEK JEROEN B C/O ALLOVIR, INC. 139 MAIN STREET, SUITE 500 CAMBRIDGE MA 02142 0 1 0 0 Chief Commercial Officer Common Stock 2021-02-17 4 S 0 15196 39.65 D 490134 D Common Stock 2021-03-02 4 S 0 512 37.93 D 472522 D Common Stock 2021-05-18 4 S 0 15201 22.80 D 457321 D Common Stock 2021-06-03 4 S 0 508 22.87 D 456813 D Common Stock 2021-08-17 4 S 0 15205 17.82 D 441608 D Common Stock 2021-09-02 4 S 0 513 19.86 D 441095 D Common Stock 2021-09-17 4 S 0 5916 25.0781 D 435179 D Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person. As previously reported, the reporting person sold 17,100 shares of Common Stock between February 17, 2021 and March 2, 2021. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. /s/ Brett Hagen, as Attorney-in-Fact 2021-09-20